Physician

Kent Joseph Nastasi, M. D.

According to 2025 Medicare claims, Kent Nastasi, M. D. (NPI: 1588654750) practices allergy/immunology in the Winston-Salem, NC market, with the plurality of this provider's patient population coming from Forsyth, NC. This provider's primary affiliated billing organization is ALLERGY PARTNERS, PLLC (NPI: 1558351726; TIN: 561249571) and primary practice location at 27103-2932. Nastasi is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Nastasi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 233 traditional Medicare patients, billed 15,870 HCPCS/CPT codes, and received $332,521 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,572 prescription claims across 302 beneficiaries totaling $651,675 in drug costs, led by Xolair (Omalizumab). DME data shows 24 claims. Open Payments data shows 127 records totaling $2,729. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $48,871 to $332,521. Similarly, Part D prescription costs have moved sharply higher in recent years, from $293,930 to $651,675. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,874 to $170.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	294	5,196	$48,871
2016	385	6,526	$60,962
2017	336	6,067	$55,421
2018	351	6,783	$65,420
2019	373	9,979	$165,854
2020	333	10,594	$237,186
2021	291	10,431	$269,398
2022	292	13,615	$348,109
2023	288	16,694	$360,365
2024	233	15,870	$332,521

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	227	1,414	$293,930
2016	221	1,364	$195,213
2017	252	1,522	$258,539
2018	271	1,556	$391,996
2019	297	1,578	$341,999
2020	270	1,558	$342,568
2021	285	1,576	$461,696
2022	297	1,700	$739,686
2023	307	1,706	$752,222
2024	302	1,572	$651,675

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	131	$59,034
2016	N/R	116	$67,779
2017	N/R	59	$42,473
2018	N/R	89	$41,374
2019	N/R	55	$40,586
2020	N/R	50	$43,398
2021	N/R	33	$40,442
2022	N/R	40	$54,299
2023	N/R	24	$35,925
2024	N/R	24	$37,801

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	47	61	$84
95165	Professional service for preparation and provision of 1 or more antigens	59	990	$9
95117	Professional service for multiple injections of allergen	94	622	$7
95115	Professional service for single injection of allergen	46	292	$6
96160	Administration and interpretation of patient-focused health risk assessment	67	138	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xolair	Omalizumab	44	1,232	$177,387
Tezspire	Tezepelumab-Ekko	21	588	$87,266
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	108	3,780	$81,530
Dupixent Syringe	Dupilumab	18	504	$69,826
Nucala	Mepolizumab	15	420	$57,332

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	12	$37,682
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	12	$118

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$2,729	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kent Joseph Nastasi, M. D.?

Tedicare shows public-source Medicare data for Kent Joseph Nastasi, M. D. (NPI 1588654750), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kent Joseph Nastasi, M. D. have ACO affiliation data?

Kent Joseph Nastasi, M. D. is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Kent Joseph Nastasi, M. D.?

Kent Joseph Nastasi, M. D. is linked to ALLERGY PARTNERS, PLLC (billing NPI 1558351726) in the available physician profile data.

Does Kent Joseph Nastasi, M. D. have Open Payments data?

Kent Joseph Nastasi, M. D. has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.